Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05508789 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Name: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) — clinical trial record (NCT05508789)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 3

SponsorEli Lilly and Company

Started2022-10-10

View on ClinicalTrials.gov ↗

The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.

Amendment history 1 change detected by DataLookout

2026-05-12

Trial status changed: Recruiting → Active, Not Recruiting

Trial Details

NCT Number	NCT05508789
Lead Sponsor	Eli Lilly and Company
Conditions	Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders +1 more
Enrollment	1,500 participants
Start Date	2022-10-10
Primary Completion	2028-05 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-07-16